PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer - Abstract

The clinical trial PREFERE aims to recruit 7600 patients with "early intermediate" prostate cancer.

The goal is to confirm noninferiority of cancer-specific survival after external-beam radiotherapy, permanent seed implantation, or active surveillance compared with radical prostatectomy.

Written by:
Wiegel T, Stöckle M, Bartkowiak D.   Are you the author?
Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany; Department of Urology, University Hospital Homburg/Saar, Homburg, Germany.  

Reference: Eur Urol. 2014 Sep 27. pii: S0302-2838(14)00911-7.
doi: 10.1016/j.eururo.2014.09.016


PubMed Abstract
PMID: 25269383

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe